Covered recipient · General Payments record
BRYAN A FALLER
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$1,328.50
62 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,328.50 | 62 |
By paying entity
PY2024 · entire year · sorted by reported total
Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
BRYAN A FALLER
NPI 1790870178 · CMS profile ID 127090
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
SAINT LOUIS, MO
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1790870178?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- BRYAN A FALLER, NPI 1790870178, CMS profile ID 127090. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790870178?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). BRYAN A FALLER, NPI 1790870178, CMS profile ID 127090. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790870178?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- BRYAN A FALLER, NPI 1790870178, CMS profile ID 127090, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1790870178?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
62 matching records · $1,328.50 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–62 of 62.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| PharmaEssentia USA Corporation | $19.55 | 03/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137302656 | CMS |
| Regeneron Healthcare Solutions, Inc. | $25.20 | 03/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114045149 | CMS |
| Incyte Corporation | $18.76 | 03/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141273752 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $19.99 | 03/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118157745 | CMS |
| PFIZER INC. | $24.83 | 02/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131275846 | CMS |
| E.R. Squibb & Sons, L.L.C. | $21.62 | 02/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101660210 | CMS |
| Novartis Pharmaceuticals Corporation | $22.95 | 02/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086895805 | CMS |
| MorphoSys, US Inc. | $19.99 | 01/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1071901606 | CMS |
| ABBVIE INC. | $34.95 | 01/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103707765 | CMS |
| EMD Serono, Inc. | $19.09 | 01/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120212012 | CMS |
| Genentech USA, Inc. | $24.74 | 01/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132983405 | CMS |
| Genentech USA, Inc. | $24.15 | 01/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132983407 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $478.00 | 1 |
| PY2025 | Principal investigator | $765,380.66 | 50 |
| PY2024 | Principal investigator | $4,889.13 | 14 |
| PY2023 | Principal investigator | $6,525.07 | 10 |
| PY2022 | Principal investigator | $10,650.05 | 12 |
| PY2021 | Principal investigator | $18,545.61 | 12 |
| PY2020 | Principal investigator | $15,375.17 | 4 |
| PY2019 | Principal investigator | $19,938.76 | 9 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
51 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $500.00 | 11/19/2025 | Covered Recipient Teaching Hospital MISSOURI BAPTIST MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722430 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Covered Recipient Teaching Hospital MISSOURI BAPTIST MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722231 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Covered Recipient Teaching Hospital MISSOURI BAPTIST MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722233 |
| Recipient | Eli Lilly and Company | $478.00 | 09/24/2025 | Covered Recipient Physician | A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF OLOMORASIB IN COMBINATION WITH STANDARD OF CARE IMMUNOTHERAPY IN PARTICIPANTS WITH RESECTED OR UNRESECTABLE KRAS G12C-MUTANT, NON-SMALL CELL LUNG CANCER - SUNRAY-02 | No dispute reported | 06/30/2026 | 1187872905 |
| Principal investigator 1 | Celgene Corporation | $4,000.00 | 07/30/2025 | Covered Recipient Teaching Hospital Missouri Baptist Medical Center | Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. The purpose of the Connect Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. | No dispute reported | 06/30/2026 | 1222304881 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Covered Recipient Teaching Hospital MISSOURI BAPTIST MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228723586 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Covered Recipient Teaching Hospital MISSOURI BAPTIST MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228786258 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Covered Recipient Teaching Hospital MISSOURI BAPTIST MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228787570 |
| Principal investigator 1 | Genentech, Inc. | $3,705.11 | 06/09/2025 | Non-covered Recipient Entity MAYO CLINIC ROCHESTER REMIT PROCESSING | Chemo trastuzumab vs chemo trastuzumab pertuzumab | No dispute reported | 06/30/2026 | 1211622958 |
| Principal investigator 1 | AstraZeneca UK Limited | $19,749.88 | 05/30/2025 | Covered Recipient Teaching Hospital Missouri Baptist Medical Center | CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease | No dispute reported | 06/30/2026 | 1185552727 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 05/30/2025 | Covered Recipient Teaching Hospital MISSOURI BAPTIST MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228786254 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 05/30/2025 | Covered Recipient Teaching Hospital MISSOURI BAPTIST MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228786769 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 05/30/2025 | Covered Recipient Teaching Hospital MISSOURI BAPTIST MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228786809 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 05/30/2025 | Covered Recipient Teaching Hospital MISSOURI BAPTIST MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228787923 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 04/29/2025 | Covered Recipient Teaching Hospital MISSOURI BAPTIST MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228785871 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 04/29/2025 | Covered Recipient Teaching Hospital MISSOURI BAPTIST MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228785874 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 04/29/2025 | Covered Recipient Teaching Hospital MISSOURI BAPTIST MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228786207 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 04/29/2025 | Covered Recipient Teaching Hospital MISSOURI BAPTIST MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228786653 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 04/29/2025 | Covered Recipient Teaching Hospital MISSOURI BAPTIST MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228786813 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 04/29/2025 | Covered Recipient Teaching Hospital MISSOURI BAPTIST MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228787721 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 04/29/2025 | Covered Recipient Teaching Hospital MISSOURI BAPTIST MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228788547 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,655.81 | 04/07/2025 | Non-covered Recipient Entity Siu School Of Medicine | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1235993677 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,655.81 | 04/07/2025 | Non-covered Recipient Entity Sainte Genevieve County Memorial Hospital | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1235994063 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,655.81 | 04/07/2025 | Non-covered Recipient Entity Parkland Health Center | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1235994762 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,655.81 | 04/07/2025 | Non-covered Recipient Entity Missouri Baptist Sullivan Hospital | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1235995657 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,655.81 | 04/07/2025 | Non-covered Recipient Entity Illinois Cancercare, PC | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1235996725 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,655.81 | 04/07/2025 | Non-covered Recipient Entity Illinois Cancercare, PC | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1235996727 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,655.81 | 04/07/2025 | Non-covered Recipient Entity Illinois Cancercare, PC | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1235996729 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,655.81 | 04/07/2025 | Non-covered Recipient Entity Illinois Cancercare, PC | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1235996731 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,655.81 | 04/07/2025 | Non-covered Recipient Entity Illinois Cancercare, PC | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1235996733 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,655.81 | 04/07/2025 | Non-covered Recipient Entity Illinois Cancercare, PC | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1235996735 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,655.81 | 04/07/2025 | Non-covered Recipient Entity Illinois Cancercare, PC | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1235996737 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,655.81 | 04/07/2025 | Non-covered Recipient Entity Illinois Cancercare, PC | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1235996739 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,655.81 | 04/07/2025 | Non-covered Recipient Entity Illinois Cancercare, PC | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1235996741 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,655.81 | 04/07/2025 | Non-covered Recipient Entity Illinois Cancercare, PC | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1235996743 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,655.81 | 04/07/2025 | Non-covered Recipient Entity Illinois Cancercare, PC | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1235996745 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,655.81 | 04/07/2025 | Non-covered Recipient Entity Illinois Cancercare, PC | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1235996747 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,655.81 | 04/07/2025 | Non-covered Recipient Entity Illinois Cancercare, PC | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1235996749 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,655.81 | 04/07/2025 | Non-covered Recipient Entity Illinois Cancercare, PC | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1235996751 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,655.81 | 04/07/2025 | Non-covered Recipient Entity Cancer Care Specialists Of Illinois | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1235998434 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,655.81 | 04/07/2025 | Non-covered Recipient Entity Cancer Care Specialists Of Illinois | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1235998436 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,655.81 | 04/07/2025 | Non-covered Recipient Entity Cancer Care Specialists Of Illinois | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1235998438 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,655.81 | 04/07/2025 | Non-covered Recipient Entity Bjc Medical Group Outpatient Center At Sunset Hills Adult Medicine | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1235998598 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,655.81 | 04/07/2025 | Covered Recipient Teaching Hospital St. Elizabeth Hospital | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1236000238 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $53,311.62 | 04/07/2025 | Covered Recipient Teaching Hospital Springfield Memorial Hospital | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1236000250 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,655.81 | 04/07/2025 | Covered Recipient Teaching Hospital Missouri Baptist Medical Center | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1236000604 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,655.81 | 04/07/2025 | Covered Recipient Teaching Hospital Decatur Memorial Hospital | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) | No dispute reported | 06/30/2026 | 1236001300 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 03/12/2025 | Covered Recipient Teaching Hospital MISSOURI BAPTIST MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228786426 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 03/12/2025 | Covered Recipient Teaching Hospital MISSOURI BAPTIST MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228787927 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 03/12/2025 | Covered Recipient Teaching Hospital MISSOURI BAPTIST MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228788709 |
| Principal investigator 1 | PFIZER INC. | $10,000.00 | 02/03/2025 | Covered Recipient Teaching Hospital MISSOURI BAPTIST MEDICAL CENTER | THE COMPASSHER2 TRIALS COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2POSITIVE BREAST CANCER COMPASSHER2 RESIDUAL DISEASE RD A DOUBLEBLINDED PHASE III RANDOMIZED TRIAL OF TDM1 COMPARED WITH TDM1 AND TUCATINIB | No dispute reported | 06/30/2026 | 1228784129 |